Semaglutide (Ozempic, Wegovy, Rybelsus) is the most widely prescribed GLP-1 receptor agonist, and one of the most studied pharmacological agents in metabolic disease research. Its effects extend well beyond glycaemic control encompassing appetite regulation, adipose tissue biology, hepatic function, cardiovascular risk markers, and inflammatory mediators. For researchers conducting mechanistic studies, pharmacodynamic assessments, or comparing Semaglutide to other GLP-1 agonists, selecting the right biomarkers and understanding what drives each change is essential for generating interpretable data. This article provides a systematic review of the biomarkers most meaningfully altered by Semaglutide, organised by biological system, with practical guidance on measurement.
Why Semaglutide Alters So Many Biomarkers: A Multi-Tissue Receptor
Semaglutide is a C18 fatty diacid-acylated GLP-1 analog with a seven-day half-life that maintains sustained GLP-1R activation across tissues. Unlike short-acting GLP-1R agonists (Exenatide, Lixisenatide), which primarily affect postprandial gastric emptying, Semaglutide’s extended exposure engages GLP-1R across the full range of tissues where the receptor is expressed: pancreatic islets, hypothalamus, brainstem, stomach, heart, kidneys, and at lower expression levels adipose tissue and the liver. Each of these engagement sites contributes a distinct set of biomarker changes.
Semaglutide’s biomarker effects can be divided into those that are direct resulting from GLP-1R activation in a specific tissue and those that are indirect resulting from changes in body weight, caloric intake, adipose tissue mass, or insulin sensitivity that cascade through multiple systems. Both types are biologically meaningful and measurable, but they require different assays and different timing of measurement within a study.
Pancreatic and Glycaemic Biomarkers: The Primary Pharmacodynamic Axis
Insulin and C-Peptide
GLP-1R activation on pancreatic beta cells amplifies glucose-stimulated insulin secretion (GSIS) via the cAMP-PKA axis. In the fasting state, Semaglutide does not substantially increase insulin the glucose-dependence of GLP-1R-mediated GSIS means insulin is not stimulated below the glucose threshold for normal physiological KATP channel closure. In postprandial or glucose-clamped conditions, Semaglutide markedly amplifies the insulin response.
For researchers, this means that fasting insulin measurement is an appropriate surrogate for insulin resistance (via HOMA-IR: fasting insulin fasting glucose / 22.5) rather than a direct measure of Semaglutide’s insulinotropic effect. Postprandial insulin or hyperglycaemic clamp-derived first- and second-phase insulin responses are required to directly demonstrate GLP-1R-mediated GSIS enhancement.
C-peptide is preferable to insulin when exogenous insulin is being administered alongside Semaglutide (in insulin combination studies), because C-peptide is co-secreted with endogenous insulin in equimolar amounts but is not present in synthetic insulin preparations. C-peptide measurement therefore reflects endogenous beta-cell secretory function specifically, uncontaminated by exogenous insulin signal.
Glucagon
GLP-1R is expressed on pancreatic alpha-cells. At elevated glucose concentrations, GLP-1R activation suppresses glucagon secretion an anti-hyperglycaemic effect independent of the insulin axis. Semaglutide measurably reduces postprandial and post-hyperglycaemic glucagon. This glucagon suppression is glucose-dependent in the same way as insulin stimulation: at hypoglycaemia, glucagon counterregulatory responses are largely preserved, which is why GLP-1 agonists alone have low hypoglycaemia risk.
Glucagon measurement is relevant in mechanistic studies examining the alpha-cell contribution to Semaglutide’s glycaemic effects, and in studies of post-bariatric or post-pancreatic surgery patients where glucagon dysregulation may co-exist with altered GLP-1 biology.
Fasting Glucose and HbA1c
Fasting plasma glucose falls with Semaglutide through multiple mechanisms: reduced hepatic glucose output (via suppressed glucagon), improved peripheral insulin sensitivity (primarily indirect, via weight loss), and in the postprandial window, slower gastric emptying reducing glucose absorption rate. HbA1c reductions of 1.5-2.0% are typical with Semaglutide 1.0 mg/week in clinical trials. For mechanistic research, glucose and HbA1c are outcome measures rather than mechanistic biomarkers, but they provide essential context for interpreting other biomarker changes.
Appetite Regulatory Hormones: The Drivers of Weight Loss
Ghrelin
Ghrelin is an orexigenic peptide secreted by gastric X/A-like cells that rises before meals (hunger signal) and falls postprandially. It acts on hypothalamic GHS-R1a receptors to increase food intake and promote fat deposition. Semaglutide consistently reduces circulating total ghrelin, with reductions of 15-30% reported in clinical studies at 26-68 weeks. The mechanism is indirect Semaglutide does not directly stimulate ghrelin-suppressing pathways but appears to reset the fasting ghrelin set point through sustained hypothalamic GLP-1R activation, weight loss, and changes in adiposity. Measuring ghrelin (fasting) provides evidence for the appetite suppression component of Semaglutide’s weight loss mechanism, as distinct from the metabolic changes discussed below.
For researchers: both total ghrelin and acylated (active) ghrelin can be measured. Total ghrelin reflects overall ghrelin secretory output; acylated ghrelin is the biologically active form that activates GHS-R1a. Both decrease with Semaglutide treatment. Acylated ghrelin ELISA require careful sample handling acylated ghrelin is rapidly de-acylated by plasma esterases, necessitating collection into PMSF or p-hydroxymercuribenzoate to preserve the acyl group.
Leptin
Leptin is secreted by adipocytes in proportion to fat mass. As Semaglutide reduces total fat mass (Wegovy produces 12-15% body weight reduction, predominantly fat), circulating leptin falls proportionally typically 30-50% reductions from baseline in studies achieving 10-15% weight loss. This leptin reduction is largely a secondary consequence of fat mass loss rather than a direct pharmacological effect of GLP-1R signalling.
The significance: falling leptin during Semaglutide treatment is a biomarker of achieved fat mass reduction, not a unique pharmacological action. Researchers must distinguish this from hypothalamic leptin sensitivity changes Semaglutide may improve hypothalamic leptin signalling (reducing leptin resistance) through effects on hypothalamic inflammation, but this cannot be inferred from circulating leptin alone and requires more specialised assays.
Adipokines and Adipose Tissue Biology: What the Fat Depot Reports
Adiponectin
Adiponectin is the most clinically significant adipokine altered by Semaglutide. Secreted by healthy, non-hypertrophied adipocytes, adiponectin falls in obesity and rises with weight loss and adipose tissue normalisation. Semaglutide produces consistent and clinically meaningful adiponectin increases typically 20-45% above baseline in studies achieving 10-15% body weight reduction. This increase reflects improved adipocyte biology: as excess fat is lost, adipocytes become smaller and resume normal secretory function.
Adiponectin is particularly valuable in Semaglutide mechanistic studies because it provides an integrated readout of adipose tissue health improvement beyond weight reduction alone. Some patients achieve comparable weight loss with different interventions (caloric restriction vs Semaglutide) but differential adiponectin responses suggest that GLP-1R agonism may have qualitative adipose effects beyond simple mass reduction. High-molecular-weight (HMW) adiponectin the most biologically active oligomeric form can be measured separately and is the preferred form for insulin sensitisation studies.
Resistin and Visfatin
Both resistin and visfatin (NAMPT) are reduced by Semaglutide treatment, primarily via reduction in total adipose tissue mass and improvement in adipose tissue inflammatory status. These changes are less dramatic than the adiponectin response and are less frequently reported as primary endpoints, but they contribute to the overall picture of improved adipose endocrine function. Resistin reduction is more reliably demonstrated in rodent models (where resistin is primarily adipocyte-derived) than in humans (where resistin is substantially macrophage/monocyte-derived and may reflect inflammatory state more than fat mass per se).
Hepatic Biomarkers: The NASH Pharmacodynamics Story
ALT and AST
Semaglutide consistently reduces serum ALT and AST in patients with NAFLD and NASH. In the PILOT-NASH Phase II trial, 59% of patients in the highest Semaglutide dose group achieved NASH resolution (vs 17% placebo) at 72 weeks. ALT normalisation parallels and reflects this histological improvement. The mechanism is primarily indirect reduced hepatic lipid delivery from improved insulin sensitivity and reduced adipose lipolysis, reduced portal FFA flux, reduced de novo lipogenesis rather than direct GLP-1R hepatocyte signalling (hepatocyte GLP-1R expression is low in humans).
For researchers: ALT/AST changes during Semaglutide treatment are suitable as secondary pharmacodynamic endpoints but require careful interpretation. ALT fluctuates with acute illness, exercise, alcohol intake, and medication changes. Serial measurements at consistent time points (pre-dose, to standardise for GLP-1-mediated gastric emptying effects on sample timing) are recommended.
FGF-21
As hepatic steatosis resolves with Semaglutide treatment, the hepatic metabolic stress driving FGF-21 upregulation diminishes, and circulating FGF-21 falls. FGF-21 reductions of 20 40% have been reported in clinical studies of Semaglutide in NAFLD/NASH. Given that FGF-21 elevation reflects the degree of hepatic lipid stress, its reduction is a sensitive marker of hepatic response to Semaglutide potentially more sensitive than ALT alone, as FGF-21 begins falling before transaminases normalise in some patients.
The practical caveat: FGF-21 has high inter-individual variability and a circadian rhythm (levels are higher in the morning and after fasting). Standardising sampling time ideally fasting, morning is important for reliable longitudinal comparisons.
CK-18
In NASH patients, Semaglutide reduces circulating CK-18, reflecting reduced hepatocyte apoptosis as steatohepatitis resolves. CK-18 changes during Semaglutide treatment correlate with histological NASH resolution on biopsy making it the most mechanistically direct serum biomarker for monitoring Semaglutide’s hepatic pharmacodynamic effect. Studies have shown that CK-18 reduction at 12-24 weeks predicts histological NASH resolution at 48-72 weeks, suggesting it may be useful as an early on-treatment biomarker of hepatic response.
Inflammatory Biomarkers: Adipose and Systemic Inflammation
TNF-a and IL-6
Semaglutide reduces circulating TNF-a and IL-6, primarily via reduction in adipose tissue macrophage activation. As total fat mass decreases and adipocyte hypertrophy resolves, the resident macrophage population within adipose tissue is reduced and shifts toward a less activated phenotype. Since adipose tissue macrophages are a major source of circulating TNF-a and IL-6 in obese individuals, their suppression drives the observed systemic cytokine reductions.
There may also be a direct GLP-1R anti-inflammatory effect in macrophages GLP-1R is expressed on macrophages and monocytes, and GLP-1R activation has been shown to suppress LPS-stimulated NF-B activation and cytokine production in vitro. Whether this direct anti-inflammatory effect contributes meaningfully to the in vivo cytokine reductions seen with Semaglutide, or whether the effect is predominantly secondary to fat mass reduction, is not definitively resolved.
For researchers using TNF-a and IL-6 as Semaglutide pharmacodynamic endpoints: calibration against NIBSC/WHO international reference standards is strongly recommended. Non-calibrated cytokine ELISA show substantial inter-laboratory and inter-kit variability that makes multi-timepoint or multi-site comparisons unreliable. NIBSC-calibrated assays report results in pg/mL (or IU/mL) traceable to a universal reference standard.
hsCRP
High-sensitivity CRP is an acute-phase protein synthesised by the liver in response to IL-6 stimulation. As IL-6 falls during Semaglutide treatment, hsCRP falls proportionally by 25-40% in most clinical studies. hsCRP is not a direct pharmacodynamic marker of GLP-1R engagement but is a convenient, standardised clinical laboratory measure of systemic low-grade inflammation. Its reduction with Semaglutide has cardiovascular risk implications, as elevated hsCRP is an independent cardiovascular risk factor. For mechanistic research, measuring the upstream drivers (TNF-a, IL-6) provides more biological information than hsCRP alone.
Cardiovascular Biomarkers: The SUSTAIN-6 and SELECT Context
Semaglutide’s cardiovascular benefit demonstrated in SUSTAIN-6 (injectable, T2DM) and the landmark SELECT trial (injectable, without diabetes, with established CVD) has generated interest in the cardiovascular biomarker changes that accompany its use. SELECT showed a 20% reduction in major adverse cardiovascular events (MACE) with Semaglutide 2.4 mg in people with obesity and established cardiovascular disease but without T2DM the first demonstration of cardiovascular benefit for a weight-loss drug in a non-diabetic population.
The biomarkers most relevant to cardiovascular risk reduction with Semaglutide include: blood pressure (both systolic and diastolic fall, by ~3 – 5 mmHg, largely secondary to weight loss); LDL cholesterol (modestly reduced, by 5-10%); triglycerides (reduced by 15-25%, partially via reduced hepatic VLDL production secondary to reduced hepatic fat); HDL cholesterol (mildly increased); and cardiac troponin / BNP in relevant patient populations (evidence of reduced myocardial stress).
For researchers focused on the cardiovascular pharmacodynamics of Semaglutide, lipid panels and blood pressure are the most accessible biomarkers, while more mechanistic studies may incorporate adiponectin (which has direct cardioprotective effects via AMPK activation in cardiomyocytes), BNP/NT-proBNP in heart failure contexts, and inflammatory markers.
Practical Guidance: Timing, Matrices, and Panel Design
Several practical considerations affect the reliability of biomarker measurement in Semaglutide studies that are worth addressing directly.
Sampling timing relative to dose: Semaglutide has a seven-day half-life and is dosed weekly. Plasma drug concentrations are highest 24 48 hours post-injection and lowest just before the next dose (trough). For pharmacodynamic biomarkers, sampling should be standardised to the same time point relative to the last injection across all subjects and visits typically at trough (just before the next weekly dose) for consistency.
Fasting state: Adipokines (particularly adiponectin and leptin), FGF-21, ghrelin, and glucose-related markers all show postprandial variation. All samples in longitudinal studies should be taken after a consistent fasting period at least 8 hours, ideally 10-12 hours.
Matrix choice: Serum is the conventional matrix for most adipokine and hepatic biomarker assays. EDTA plasma is preferred for some analytes (notably ghrelin active form, which is unstable in serum, and drug PK assays for Semaglutide itself using KBI5030). Verify the validated matrix for each specific assay before study start.
| Biomarker | Direction with Semaglutide | Mechanism (Direct/Indirect) | Best Sampling Condition | Notes |
|---|---|---|---|---|
| Adiponectin | 20 - 45% | Indirect fat mass reduction + adipocyte normalisation | Fasting serum | HMW form preferred for IR studies |
| Leptin | 30 - 50% | Indirect proportional to fat mass loss | Fasting serum or EDTA plasma | Reflects fat mass change, not direct GLP-1R effect |
| Ghrelin (total) | 15 - 30% | Indirect hypothalamic reset + weight loss | Fasting, morning | For acylated: add PMSF to collection tube |
| FGF-21 | 20 - 40% in NASH | Indirect hepatic steatosis resolution | Fasting, morning (circadian variation) | High inter-individual variability |
| CK-18 | in NASH | Indirect reduced hepatocyte apoptosis | Fasting serum | M30 = apoptosis-specific; M65 = total |
| ALT / AST | in NAFLD/NASH | Indirect hepatic steatosis resolution | Fasting serum | Standardise timing; confounders many |
| TNF-a | Indirect (adipose) + possible direct GLP-1R (macrophage) | Serum or EDTA plasma | Use NIBSC-calibrated assay for multi-site studies | |
| IL-6 | Indirect (adipose macrophage) + possible direct | Serum or EDTA plasma | NIBSC-calibrated assay recommended | |
| Glucagon | postprandial | Direct GLP-1R on alpha-cells (glucose-dependent) | Postprandial or hyperglycaemic clamp | Fasting glucagon less informative |
| Semaglutide (drug) | Reference for PK/PD correlation | Drug ELISA KBI5030 competitive ELISA | Trough (pre-dose) or peak (24 - 48h post-dose) | Do not use GLP-1 hormone ELISA for drug measurement |
Critical point on drug vs hormone assays: Semaglutide ELISA (KBI5030) measures the drug molecule specifically. It does not measure endogenous GLP-1. Endogenous GLP-1 ELISA measures the L-cell hormone. These are different analytes, different assay formats, and different clinical questions. Substituting one for the other produces meaningless data. In studies of Semaglutide mechanism of action, you may need both: the drug PK assay to confirm exposure, and the endogenous GLP-1 assay to examine whether Semaglutide alters L-cell secretion (it does GLP-1R agonists increase endogenous GLP-1 via reduced DPP-4-mediated degradation and possible L-cell feedback).
